Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 121.58 -0.01 (-0.01%) Market Cap: 7.35 Bil Enterprise Value: 10.93 Bil PE Ratio: 17.12 PB Ratio: 1.76 GF Score: 85/100

Zymeworks Inc & Jazz Pharmaceuticals PLC - Zanidatamab License and Collaboration Agreement Call Transcript

Oct 19, 2022 / 12:00PM GMT
Release Date Price: $132.33 (-2.04%)
Operator

Thank you for standing by. This is the conference operator. Welcome to Zymeworks zanidatamab Licensing Agreement webcast. (Operator Instructions) And the webcast is being recorded.

I would now like to turn the conference over to Jack Spinks, Head of Investor Relations at Zymeworks. Jack, please go ahead.

Jack W. Spinks
Zymeworks Inc. - Manager of IR

Good morning, and welcome, everyone. Thank you for joining. My name is Jack Spinks, Associate Director of Investor Relations here at Zymeworks. Before I turn the call over to Ken, our Chair and CEO, who will speak to you today about this morning's announcement of Zymeworks Licensing and Global Development collaboration with Jazz Pharmaceuticals, I'd like to first briefly remind you that during today's call, we'll be making forward-looking statements.

Forward-looking statements to be identified by words such as should, would, will, continue, may, potential, initiate, look forward to, expect, believe, plan, anticipate, enable and similar words. Forward-looking statements are based upon our current

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot